196 Results

People

  1. Drilon
    Drilon
  2. Aghajanian
    Aghajanian
  3. Abdel-Wahab
    Abdel-Wahab
  4. De Angelis
    De Angelis
  5. Fornier
    Fornier
  6. Motzer
    Motzer
  7. Zelenetz
    Zelenetz
  8. Abou-Alfa
    Abou-Alfa
  9. Basch
    Basch
  10. Fury
    Fury

Groups

  1. Department of Medicine (134)
  2. Solid Tumor Oncology Division (84)
  3. Hematologic Malignancies, Division of (48)
  4. Center for Hematologic Malignancies (41)
  5. Survivorship Research (25)
  6. GSK Faculty (23)
  7. Adult Leukemia (20)
  8. Thoracic Oncology (19)
  9. Genitourinary Oncology Service (18)
  10. Tow Center for Developmental Oncology (TCDO) (17)
  1. "dizziness"
Formats
  1. Journal Article (180)
  2. Review (12)
  3. Research Letter (2)
  4. Editorial (1)
  5. Guidelines (1)
Groups
  1. Department of Medicine (134)
  2. Solid Tumor Oncology Division (84)
  3. Hematologic Malignancies, Division of (48)
  4. Center for Hematologic Malignancies (41)
  5. Survivorship Research (25)
  6. GSK Faculty (23)

More Groups

People
  1. Alexander Drilon (10)
  2. Carol Aghajanian (7)
  3. Alan Ho (5)
  4. Andrew Zelenetz (5)
  5. Lisa De Angelis (5)
  6. Monica Fornier (5)

More People

Years
  1. 2025 (4)
  2. 2024 (21)
  3. 2023 (20)
  4. 2022 (8)
  5. 2021 (7)
  6. 2020 (18)

More Years

Publications
  1. Clinical Cancer Research (16)
  2. Journal of Clinical Oncology (13)
  3. Lancet Oncology (13)
  4. Blood (9)
  5. Annals of Oncology (8)
  6. Cancer (8)

More Publications

Publishers
  1. Elsevier Inc. (18)
  2. Elsevier Science, Inc. (18)
  3. Oxford University Press (17)
  4. American Association for Cancer Research (16)
  5. Nature Publishing Group (16)
  6. American Society of Clinical Oncology (13)

More Publishers

Results (196)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials
    Journal Article

    Hong, D. S.; DuBois, S. G.; Kummar, S.; Farago, A. F.; Albert, C. M.; Rohrberg, K. S.; van Tilburg, C. M.; Nagasubramanian, R.; Berlin, J. D.; Federman, N.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: The ANNOUNCE randomized clinical trial
    Journal Article

    Tap, W. D.; Wagner, A. J.; Schöffski, P.; Martin-Broto, J.; Krarup-Hansen, A.; Ganjoo, K. N.; Yen, C. C.; Abdul Razak, A. R.; Spira, A.; Kawai, A.; more...
    JAMA - Journal of the American Medical Association (2020)

    Fulltext@MSK | Save
  • Clinician vs patient reporting of baseline and postbaseline symptoms for adverse event assessment in cancer clinical trials
    Research Letter

    Atkinson, T. M.; Dueck, A. C.; Satele, D. V.; Thanarajasingam, G.; Lafky, J. M.; Sloan, J. A.; Basch, E.
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: Interim results from a multicentre, open-label, phase 1b study
    Journal Article

    Sequist, L. V.; Han, J. Y.; Ahn, M. J.; Cho, B. C.; Yu, H.; Kim, S. W.; Yang, J. C. H.; Lee, J. S.; Su, W. C.; Kowalski, D.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • TATTON: A multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
    Journal Article

    Oxnard, G. R.; Yang, J. C. H.; Yu, H.; Kim, S. W.; Saka, H.; Horn, L.; Goto, K.; Ohe, Y.; Mann, H.; Thress, K. S.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials
    Journal Article

    Doebele, R. C.; Drilon, A.; Paz-Ares, L.; Siena, S.; Shaw, A. T.; Farago, A. F.; Blakely, C. M.; Seto, T.; Cho, B. C.; Tosi, D.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • A phase 1b study of cetuximab and BYL719 (alpelisib) concurrent with intensity modulated radiation therapy in stage III-IVB head and neck squamous cell carcinoma
    Journal Article

    Dunn, L. A.; Riaz, N.; Fury, M. G.; McBride, S. M.; Michel, L.; Lee, N. Y.; Sherman, E. J.; Baxi, S. S.; Haque, S. S.; Katabi, N.; more...
    International Journal of Radiation Oncology, Biology, Physics (2020)

    Fulltext@MSK | Save
  • PD-1 blockade in advanced adrenocortical carcinoma
    Journal Article

    Raj, N.; Zheng, Y.; Kelly, V.; Katz, S. S.; Chou, J.; Do, R. K. G.; Capanu, M.; Zamarin, D.; Saltz, L. B.; Ariyan, C. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
    Journal Article

    Yacoub, A.; Mascarenhas, J.; Kosiorek, H.; Prchal, J. T.; Berenzon, D.; Baer, M. R.; Ritchie, E.; Silver, R. T.; Kessler, C.; Winton, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): A phase 3, multicentre, open-label, single-arm trial
    Journal Article

    Fleseriu, M.; Pivonello, R.; Elenkova, A.; Salvatori, R.; Auchus, R. J.; Feelders, R. A.; Geer, E. B.; Greenman, Y.; Witek, P.; Cohen, F.; more...
    Lancet Diabetes & Endocrinology (2019)

    Fulltext@MSK | Save